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Abstract: We recently described the synthesis and characterization of a novel difluorinatedbenzylidene analog of 
curcumin, commonly referred as CDF, which demonstrated significantly enhanced bioavailability and in vivo an-
ticancer activity. CDF targets many factors similar to curcumin, albeit with more potency, as reported previously. 
To further highlight this differential behavior of CDF, we chose matrix metalloproteinase protein MMP-2 which is 
involved in the processes of invasion and metastasis of human tumors. Both curcumin and CDF were characterized 
for their binding characteristics using in silico docking studies; they were also evaluated via biological assays involv-
ing gelatin zymography, miRNA analysis, invasion assays and ELISA. CDF was found to inhibit MMP-2 expression 
and activity in A549 and H1299 NSCLC cells much more effectively than curcumin, validating molecular modeling 
results. miR-874, an MMP-2-targeting miRNA, was up-regulated by CDF. Thus, it appears that CDF can inhibit MMP-2 
through multiple mechanisms. Our results are suggestive of a more potent inhibition of invasion and metastasis by 
CDF, compared to curcumin, thus warranting its further evaluation as an effective anticancer agent. 
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Introduction
Curcumin (diferuloylmethane) is a nutraceutical 
obtained from plant Curcuma longa, which is 
commonly used as a spice in tropical Southeast 
Asia. It has been extensively investigated for its 
putative chemo-preventive and therapeutic 
uses. Despite numerous pre-clinical studies 
detailing its beneficial effects against various 
human cancers, its entry into the clinical prac-
tice has been severely limited due to poor bio-
availability and rapid metabolism [1]. In an 
attempt to overcome such limitations, investi-
gations in our laboratory led to the synthesis of 
its novel analog, viz. 3, 4-difluorobenzylidene 
curcumin, which is commonly referred to as 
CDF. This analog exhibited enhanced bioavail-
ability in pancreatic and other tissues [2, 3]. 
Subsequent investigations from our laboratory 
have also reported on potent regulation of mul-
tiple molecular targets such as NF-κB, Akt, COX-
2, IL-6, VEGF, PTEN and miRNAs by CDF [4-8]. 
Such pleiotropic action of nutraceuticals aga- 
inst multiple therapeutic targets is well-docu-
mented [9], and such a multi-targeting effect 
could be a good attribute of CDF for the preven-
tion of tumor progression and/or treatment of 
human malignancies. 
In the present study, we tested whether CDF 
can inhibit matrix metalloproteinase-2 (MMP-2), 
a member of the family of metalloproteinases. 
Members of this family are involved in the deg-
radation of extracellular matrix facilitating the 
process of metastasis, and thus MMP-2 is an 
important target to inhibit invasion and metas-
tasis. An increased expression of MMP-2 has 
been reported in various tumors including ovar-
ian, breast and prostate tumors as well as mel-
anoma [10]. Studies in recent years have sug-
gested a role of MMP-2 as cancer prognostic 
marker [11] which is associated with poor prog-
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nosis [12]. In order to validate MMP-2 as a tar-
get of CDF, docking studies were performed to 
assess the activity of CDF versus curcumin 
through MMP-2 crystal structure. CDF activity 
was compared to that of curcumin, its parent 
compound. Subsequently, biological assays 
were performed and compared for CDF and 
curcumin using gelatin zymography, invasion 
and ELISA techniques. We observed a positive 
correlation between docking studies and bio-
logical assays validating the use of our integrat-
ed approach to find new molecular target of 
CDF as a novel anticancer agent.
Materials and methods
Cell lines and reagents
The human lung adenocarcinoma cell lines 
A549 and H1299 were purchased from the 
American Type Culture Collection (Manassas, 
VA) and maintained according to the American 
Type Culture Collection’s instructions. Cells we- 
re cultured in 5% CO2-humidified atmosphere at 
37°C. The cell lines have been tested and 
authenticated through the core facility (Applied 
Genomics Technology Center at Wayne State 
University) by short tandem repeat profiling 
using the PowerPlex 16 System from Promega.
Docking studies
The NMR structure of MMP-2 protein PDB id: 
1HOV available at Protein databank [13] was 
used for docking of CDF and curcumin. Mole- 
cular docking was carried out using Auto Dock 
4.2 software program [14]. This protein con-
tains 11 models of macromolecules and previ-
ous studies have reported no differences in the 
docking studies using all 11 models. Hence, 
the catalytic domain containing S1’, S1, S2’, S3’ 
of the model 1 of PDB id 1HOV was selected for 
docking study [15]. The docking parameters 
were optimized through self-docking exercise 
carried out using the co-crystallized ligand. 
Polar hydrogen atoms were added followed by 
assignment of Kollman united atom charge to 
MMP-2. All rotatable bonds within the ligand 
were allowed to rotate freely and the molecule 
was considered rigid. For the zinc ion, the pa- 
rameter set reported by Stote and group was 
used (r=1.1 A, e=0.25 kcal mol-1 and a formal 
charge of +2e) [16]. AutoGrid program was 
used to generate 3D affinity grid fields with grid 
map of 40 × 40 × 40 points with spacing of 
0.375 Å. AutoDock tools utility was used to gen-
erate both grid and docking parameter files 
(i.e., gpf and dpf). Docking parameters were set 
to 25 automated runs for a 150 population size 
with a 2,500,000 maximum number of energy 
evaluations for each docking experiment with 
Lamarckian genetic algorithm as the search 
method. The Lamarckian Genetic Algorithm 
(LGA) was used as the search engine keeping 
other parameters to default value [17]. About 
25 conformations for curcumin and CDF were 
generated. The interactions of docked complex 
MMP-2 protein-ligand conformations, including 
hydrogen bonds and the bond lengths were 
analyzed using PyMOL v0.99rc6 [18]. The dock-
ing studies were performed at Tata Consultation 
Services, Pune.
miRNA transfections
Transfections of pre-miR-874 in A549 and 
H1299 cells were done using methodology pre-
viously described [19]. Briefly, cells were seed-
ed (2.5 × 105 cells per well) in six well plates 
and transfected with pre-miR-874 or non-spe-
cific (NS) pre-miRNA controls (Life Technologies) 
at a final concentration of 200 nM, using 
DharmaFECT transfection reagent (Dharma- 
con). After 48 hours of transfection, cells were 
passaged and transfected once again before 
evaluating the levels of target (MMP-2) by real-
time RT-PCR.
MMP-2 zymography
Activity of MMP-2 was assessed in the culture 
supernatants by gelatin zymography. A549 and 
H1299 cells were first exposed to vehicle con-
trol or curcumin/CDF (10 µM) for 72 hours. At 
the end of incubation, 50 µl of culture superna-
tant was mixed with sample buffer and resolved 
on a 12% SDS-PAGE under non-reducing condi-
tions. The gel was co-polymerized containing 
0.5 mg/ml of gelatin (Sigma, St. Louis, USA). 
Gel was washed twice for 30 minutes with 
renaturation buffer (2.5% Triton X-100) at room 
temperature before incubation in the incuba-
tion buffer (50 mM Tris-HCl pH7.5, 200 mM 
NaCl, 10 mM CaCl2, 1 μM ZnCl2) at 37°C for 16 
hours. Thereafter, gel was stained for 2 hours 
in 0.25% coomassie brilliant blue R-250 and 
then de-stained. White bands were observed 
against a blue background after de-staining, 
indicating MMP-2’s gelatinolytic activity. 
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Real-Time RT-PCR
Real-Time RT-PCR analyses were done as 
described previously [20]. Total RNA was iso-
lated using Trizol reagent (Life Technologies) 
according to the manufacturer’s instructions. 
Real-time PCR was used to quantify mRNA 
expression and the amount of RNA was normal-
ized to GAPDH expression. For miRNA analysis, 
total RNA was isolated using the mirVana 
miRNA isolation kit (Life Technologies). The lev-
els of miRNAs were determined using miRNA-
specific Taqman probes from the Taqman 
MicroRNA Assay (Life Technologies). The rela-
tive amounts of miRNA were normalized to 
RNU48.
Figure 1. Binding of curcumin and CDF in the active site of MMP-2 protein cavity as assessed by molecular docking. 
A. The surface view of docking of curcumin (blue) in the catalytic cavity of MMP-2; it interacts with Zn seen as ball 
and Arg 149 forming hydrogen bonds. It can be seen that curcumin extends in the S1’ pocket. B. The docking of 
curcumin (blue) in MMP-2 protein shown in cartoon form with the secondary structure of protein visible. The interac-
tion with Zn and Arg 149 can be seen. Arg 149 is shown as lines. C. The surface view of docking of CDF (magenta) 
in the catalytic cavity of MMP-2; the interaction of CDF with residues Leu 83, Ala 84 and His 120 forming hydrogen 
bonds can be seen. Zn atom is seen as ball. It can be seen that CDF extends in the S1’ pocket. D. The docking of CDF 
(magenta) in MMP-2 protein shown in cartoon form with the secondary structure of protein visible. The interaction 
with residues Leu 83, Ala 84 and His 120 can be seen. The interacting residues are shown as lines.
Figure 2. The cartoon view of superimposed image 
curcumin (yellow) and CDF (cyan) in the catalytic do-
main of MMP-2 protein.
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Cell invasion assay
Cell invasion assay was performed using 24 
well transwell permeable supports with 8 µM 
pores (Corning) [20]. After treatment of cells 
with curcumin/CDF or the DMSO vehicle (con-
trol) for indicated times, cells were suspended 
in serum free medium and seeded into the 
transwell inserts coated with growth factor 
reduced Matrigel (BD Biosciences). Bottom 
wells were filled with complete media. After 24 
hours, cells were stained with 4 µg/ml calcein 
AM (Life Technologies) in PBS at 37°C for 1 h. 
Cells were detached from inserts by trypsiniza-
tion and fluorescence of the invaded cells was 
read in ULTRA Multifunctional Microplate Re- 
ader (TECAN, San Jose, CA).
MMP-2 activity assay
The activity of MMP-2 was further assayed 
using human MMP-2 ELISA kit (Invitrogen, USA) 
following the vendor’s protocol. The assay is 
based on solid phase sandwich ELISA wherein 
a highly purified antibody specific for MMP-2 is 
coated onto the wells of the microtiter strips 
purchased from the vendor. During the first 
incubation, standards of known MMP-2 con-
tent, controls, and assay samples were pipet-
ted into the coated wells. A biotinylated second-
ary detection antibody was added after wash-
ing followed by further washing and addition of 
streptavidin-peroxidase enzyme bound to the 
biotinylated antibody to complete four-member 
sandwich. After a third incubation and washing 
to remove all unbound enzyme, the substrate 
solution was added. The bound enzyme acted 
upon the substrate to produce color which was 
read at 450 nM using ULTRA Multifunctional 
Microplate Reader (TECAN, San Jose, CA). The 
intensity of the color was directly proportional 
the pre-defined active site of MMP-2 protein by 
using Autodock software program. The active 
site of MMP-2 protein consists of Zn and con-
sensus (HEBGHXLGLXHS) of amino acids for Zn 
binding motif which are conserved throughout 
the MMPs and contain three histidine residues 
which are bound to Zn [21]. Previous reports 
have suggested that amino acids in the cata-
lytic cavity play an important role in binding of 
inhibitor in the protein cavity [15, 22, 23]. The 
protein cavity containing Zn and important 
amino acids was selected for docking of cur-
cumin and CDF. Both compounds were found to 
dock into the active site of MMP-2 protein cavi-
ty with a good fit (Figures 1, 2 and Table 1). The 
aryl hydroxyl group of CDF was found to be 
involved in two hydrogen bonding interactions 
with Ala 84 (both 1.8 Å) and one with Leu 83 
(2.0 Å), while one of the central diketo group 
interacted with His 120 (2.1 Å). These residues 
are found to be similar with those involved in 
the binding of known inhibitors of MMP-2 [15, 
22] and hence CDF is anticipated to exhibit pro-
nounced inhibition of MMP-2. On the other 
hand the binding interactions of curcumin are 
substantially different wherein one of the hy- 
droxyl groups on the side aryl ring is found to be 
involved in H-bonding with Arg 149 (2.5 Å) while 
the methoxy group on the other aryl ring is 
found to interact with Zn (1.9 Å) atom. Although 
these interactions yield stronger binding energy 
for curcumin (minimum binding energy: -7.35 
Kcal/mol) than CDF (minimum binding energy: 
-6.39 Kcal/mol), such binding is not expected 
to influence MMP-2 inhibition, confirmation of 
which is provided by the proceeding assays. 
Inhibition of MMP-2 activity
In order to explore the inhibition of MMP-2 
activity, we chose A549 and H1299 lung can-
Table 1. Docking analysis and consensus scores of Curcumin and CDF 
in the active site of MMP-2 protein assessed by computer modeling 
studies
Compound Minimum Binding energy (Kcal/mol)
No of hydrogen 
bonds
Amino acid  
interacting
Hydrogen bond 
Distance (Å)
Curcumin -7.35 2 Arg 149 (H) 2.5
Zn 1.9
CDF -6.39 4 Leu 83 (HN) 2.0
Ala 84 (HN) 1.8
Ala 84 (O) 1.8
His 120 (HN) 2.1
to the concentration of 
MMP-2 present.
Results
MMP-2 as a molecular 
target
To evaluate binding sta-
bilities of curcumin and 
CDF in the protein cavity 
of MMP-2, we first ass- 
essed the binding of a 
standard compound in 
Inhibition of MMP-2 by CDF
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cer cells as our models because these cells are 
known to express MMP-2 [24, 25]. We first per-
formed gelatin zymography to directly test the 
ability of curcumin and CDF to modulate the 
expression of MMP-2. Cells were treated with 
either vehicle control or 10 µM solutions of the 
two compounds. Cultures from these treated 
cells were then collected and subjected to 
zymography. We found that treatment with CDF 
more effectively inhibited the activity of MMP-2 
(Figure 3). A densitometric analysis of the 
bands revealed 16% inhibition of MMP-2 activ-
ity by curcumin and 80% inhibition by CDF in 
A549 cells (Figure 3). CDF was observed to be 
a potent inhibitor of MMP-2 activity in H1299 
cells, as well, with 82% inhibition, compared to 
58% inhibition by curcumin (Figure 3).
Transcriptional regulation of MMP-2 activity
To evaluate whether curcumin/CDF could tran-
scriptionally regulate MMP-2, we quantitated 
MMP-2 mRNA by real-time RT-PCR after treat-
ing A549 and H1299 cells with these com-
pounds for 72 hours. While curcumin inhibited 
the MMP-2 mRNA by ~23% in A549 and 30% in 
H1299 cells, the inhibition by CDF was signifi-
cantly more (p < 0.01) in both the cell lines 
tested- ~40% in A549 cells and 51% in H1299 
cells (Figure 4A). Regulatory effect of mRNA 
transcripts often involves miRNAs. miR-874 
has been reported to regulate MMP-2 levels in 
A549 and H1299 cells [25], therefore, we eval-
uated the levels of this tumor-suppressive 
miRNA in curcumin/CDF-treated cells. Both, 
curcumin and CDF were found to up-regulate 
miR-874 (Figure 4B) but the up-regulation by 
CDF was significantly more. As a proof of con-
cept, we transfected A549 and H1299 cells 
with pre-miR-874 and observed down-regula-
tion in the expression of its target MMP-2 
(Figure 4C), thus validating the regulation of 
MMP-2 by miR-874 in our model system. 
Biological significance of such MMP-2 inhibi-
tion was evaluated by invasion assays, and 
while both curcumin and CDF inhibited the inva-
sion of A549 and H1299 cells (Figure 4D), CDF 
again showed as a more potent compound. 
Figure 3. MMP-2 gelatinolytic activity (zymography) comparing the effects of curcumin and its derivative CDF. A549 
and H1299 lung cancer cells were exposed to vehicle control (DMSO) or 10 µM curcumin/CDF for 72 hours. The 
collected conditioned medium was subjected to zymography (upper panel). Densitometric analysis was performed 
on the bands from zymography gel (lower panel) where the band from control DMSO-treated sample was assigned a 
value of 1.0 and the intensity of curcumin- and CDF-treated samples’ bands was calculated relative to control band. 
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Thus, MMP-2 inhibition was correlated with the 
inhibition of invasive potential of both the cell 
lines. 
Quantitative analysis of MMP-2 activity inhibi-
tion
We assayed the secreted MMP-2 using quanti-
tative ELISA assay. A549 and H1299 cells were 
first exposed to increasing concentrations of 
curcumin and CDF for 72 hours and then 
MMP-2 levels were assayed in the culture 
supernatants. As seen in Figure 5, CDF inhibit-
ed the secretion of MMP-2 to a greater extent 
than curcumin, at all the concentrations tested. 
At the highest tested concentration of 10 µM, 
inhibition by curcumin was ~25% and ~85% by 
CDF, in A549 cells. In H1299 cells, inhibitions 
were ~39% and ~83%, respectively. Using this 
dose of 10 µM, we also tested a time-depen-
dent inhibition of MMP-2 by curcumin and CDF. 
Aliquots of conditioned media were collected at 
the indicated time periods and subjected to 
ELISA. CDF was found to be much more effec-
tive in down-regulating MMP-2 secretion, com-
pared to curcumin, at all the time periods and 
in both the cell lines (Figure 6).
Figure 4. Transcriptional regulation of MMP-2. A549 and H1299 cells were treated with 10 µM curcumin/CDF for 
72 hours and the MMP-2 mRNA transcripts (A) or the miR-874 levels (B) were quantitated by Real-Time RT-PCR. 
(C) MMP-2 mRNA levels were also measured after the cells were transfected with pre-miR-874 (NS, non-specific 
pre-miRNA control). Finally, A549 and H1299 cells treated with curcumin/CDF were subjected to invasion assays 
by plating cells in matrigel-coated inserts. The invading cells were collected by trypsinization and their fluorescence 
was quantitated using plate reader. 
Inhibition of MMP-2 by CDF
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Discussion
Whenever a novel anticancer compound is syn-
thesized that exhibits promising cytotoxic 
effects against cancer cell lines, the first and 
foremost challenge is to elucidate its molecular 
targets that are associated with its biological 
activity. This is true even for the compounds 
that are analogs of established and extensively 
studied phytochemicals. In the present study, 
we tested MMP-2 as a protein target of CDF, 
which is a novel and potent analog of curcumin. 
MMP-2 is an enzyme that belongs to the family 
of matrix metalloproteinases which are calci-
um-dependent, zinc-containing endopeptidas-
es [26, 27]. The family of human MMPs con-
sists of 23 different forms that are divided into 
six groups but are structurally and functionally 
related [27]. They are secreted in an active/
inactive zymogen or a pro-MMP form. MMP-2 
belongs to the gelatinase group of MMPs, which 
also comprises of MMP-9. This group is so 
named because these two MMPs primarily 
digest gelatin, the denatured form of collagen. 
In the present study, activity of MMP-2 was 
analyzed by a technique called substrate 
Figure 5. Concentration-dependent inhibition of MMP-2 secretion. A549 cells and H1299 were treated with indi-
cated doses of curcumin/CDF or the equivalent quantities of DMSO (vehicle control). Treatment was carried out for 
72 hours and then the samples were subjected to MMP-2 ELISA.
Figure 6. Time-course inhibition of MMP-2 secretion. A549 cells and H1299 were treated with 10 µM doses of 
curcumin/CDF or the equivalent quantities of DMSO (vehicle control) for indicated time periods. Conditioned media 
was collected at the end of different time-points and stored at -80°C until ready to be assayed. Once all the samples 
were collected, they were subjected to MMP-2 ELISA.
Inhibition of MMP-2 by CDF
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zymography. This technique identifies MMP-2 
through the degradation of its preferential sub-
strate gelatin on a polyacrylamide gel, and is 
particularly sensitive since it can detect levels 
of MMP-2 as low as 10 pg [28]. While zymogra-
phy is a reliable technique to study functional 
MMP-2s, it is not necessarily very quantitative, 
and hence we also employed ELISA technique 
for its quantitation. Inhibition of MMP-2 activity 
was determined to be 16% by zymography and 
25% by ELISA in case of curcumin while it was 
found to be 80% by zymography and 85% by 
ELISA for CDF.
The compounds used for MMP inhibition usu-
ally contain zinc binding or chelating groups like 
hydroxymate, carboxylate, phosphinate and thi- 
olate, respectively [29]. It has been observed 
that the hydroxymate group has unfavorable 
pharmacokinetics and is associated with toxici-
ties [29, 30]. Thus, new group of compounds 
need to be evolved as MMPs inhibitors. Based 
on the present work we should like to propose 
that phytochemical curcumin and its difluoben-
zylidene analog CDF are the novel MMP-2 inhib-
itors. Although Zn chelation is generally consid-
ered as a requirement for MMP inhibitors, the 
interactions with key amino acid residues in the 
catalytic site are also of foremost importance 
for influencing the inhibitory activity [31]. In 
fact, there are reports documenting that MMP-
13 inhibitors do not interact with Zn center, 
suggesting that Zn chelation is not the only cri-
teria for inhibition of MMP’s [30, 32]. The inter-
actions with the hydrophobic pocket S1’ is also 
found to be crucial for inhibiting MMP-2 [30, 
33].
Analyzing the present docking results reveals 
that both CDF and curcumin bind to the MMP-2 
in similar way as the co-crystal compound i52 
going through the S1’ pocket containing hydro-
phobic residues Phe 148, Phe 115, Thr145 
and Leu150. However, CDF showed interac-
tions with Leu 83 (S3’pocket) and Ala 84(S1 
pocket) similar to the interactions in the co-
crystal structure of hydroxamic acid inhibitor 
i52. The Ala 84 is a highly conserved residue in 
the active site of MMP protein, and thus inter-
action with this residue is considered crucial 
[15]. The active site also contains three histi-
dine residues (His 120, His124 and His 130) 
bound to the Zn atom which are highly con-
served in MMPs. In the present case, CDF was 
found to form hydrogen bond with His 120 
which is helpful in anchoring the compound in 
the active site near Zn atom while extending 
itself into the S1’ hydrophobic pocket analo-
gous to the known co-crystal inhibitor. These 
interactions similar to other known MMP-2 
inhibitors along with anchorage in the S1’ pock-
et may help explain the specificity of CDF for 
MMP-2 protein [15, 29, 34]. On the contrary, 
curcumin did not exhibit any interactions with 
the important residues although it interacted 
with Zn through its enolic hydroxyl group, result-
ing in high binding energy which alone may not 
be important for the MMP-2 inhibitory activity. 
Additionally, curcumin did show H-bonding 
interaction with Arg149 but in the neighboring 
pocket [15]. Such differential interactions with 
the important amino acid residues seem to pro-
vide the basis for the potent MMP-2 inhibitory 
activity of CDF compared to curcumin despite 
having lower binding energy in the docking site. 
Molecular docking studies are indicative of a 
post-translation regulation of target protein by 
anticancer agents. The inhibition of MMP-2 
activity by curcumin and CDF seems to stem 
from their ability to interact with the specific 
regions on the protein surface, as described 
above. Interestingly, we also observed a tran-
scriptional regulation of MMP-2 by curcumin 
and CDF which suggests the regulation of 
MMP-2 at multiple steps. As a mechanism, an 
up-regulation of miR-874 was observed. miR-
874 is a tumor suppressive miRNA [35] which 
has been shown to target MMP-2 in exactly the 
same NSCLC cell lines [25] as used in the pres-
ent study, namely A549 and H1299. Similar to 
our current observations, this study [25] also 
reported an inhibition of MMP-2 in pre-miR-
874-transfected cells. Further, this study also 
evaluated an in vivo effect of miR-874 up-regu-
lation wherein pre-miR-874 treated A549 cells 
showed much reduced orthotopic tumor bur-
den when implanted intra-thoracic in athymic 
nude mice. Combined with the invasion assays 
described by us, there is a clear biological rele-
vance of MMP-2 regulation in the NSCLC cells. 
Previous work from our laboratory has shown 
an action of CDF against membrane type 1- 
metalloproteinase (MT1-MMP), also known as 
MMP-14 [8]. CDF was observed to down-regu-
late MT1-MMP through a mechanism that 
involved up-regulation of microRNA-200s (miR-
200s) and PTEN. It is interesting to note that 
MT1-MMP is involved in the activation of MMP-2 
Inhibition of MMP-2 by CDF
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[36-38] and, thus, CDF influences multiple 
steps in MMP-2 activation cascade by interact-
ing with MT1-MMP as well as MMP-2. The miR-
200s are markers of epithelial phenotype. 
Another epithelial marker E-cadherin has re- 
cently been connected to MMP-2 and invasion 
of A549 NSCLC cells, especially because the 
loss of E-cadherin was shown to promote inva-
sion in an MMP-2-dependent manner [39]. For 
that reason, we initially used A549 cells in the 
current study as a model for the inhibition of 
MMP-2 activity. In order to rule out cell line spe-
cific effects, and also to study the transcription-
al regulation involving miR-874, as reported 
earlier [25], we corroborated our results in an- 
other NSCLC cell line, H1299. The available lit-
erature indicate a nexus of MT-MMP, MMP-2, 
miR-200s and EMT driving the processes of 
invasion and metastasis, and our current study 
indicates attenuation of such nexus by CDF, 
along with a novel regulation involving miR-874, 
a revelation that needs to be tested further in 
future studies.
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